Project: BEAM Alliance

Acronym Project N004 (Reference Number: JPIAMR_2016_N004)
Duration 01/01/2017 - 31/12/2017
Project Topic The growing risk of multi-drug resistant bacteria is a global public health crisis recognized by many governments; therefore, to combat the spread of resistant-bacteria and superbugs, new antibiotics, or alternative therapies must be developed. However, the financial attraction for R&D investment from large pharmaceutical companies is lacking, therefore, innovation in this therapeutic area is predominantly steered by small and medium pharma companies. To tackle the obstacle that superbugs present to society expeditiously, new policies and R&D incentives are needed to stimulate development in the EU. As an answer to this urgent need, we have formed the BEAM Alliance. The BEAM Alliance represents 50 European biopharmaceutical companies (small and medium size (SME)) from 12 European countries involved in developing innovative products to combat antimicrobial resistance in humans and beyond. The Working Group objective is to produce a new position paper regarding establishment of economic incentives in order to better sustain the innovation efforts of small and medium biopharmaceutical companies. The Working Group will collaborate with the existing community of stakeholders dedicated to implementing tangible strategies, including the EC DG SANTE, the UK AMR Review, WHO and the DRIVE-AB consortium. The BEAM Alliance Working Group should thus allow for expression of a unique and unprecedented opinion from the European SMEs perspective.
Website visit project website
Network JPI AMR
Call 4th Joint Call: Research Networking Programmes

Project partner

Number Name Role Country
1 Da Volterra Coordinator France
2 ABAC Therapeutics Observer Spain
3 Abgentis Observer uk
4 Absynth Biologics Observer uk
5 Adenium Biotech Observer Denmark
6 Aicuris Observer Germany
7 Alaxia Observer France
8 Allecra Observer Germany
9 Antabio Observer France
10 AntibioTx Observer Denmark
11 Arsanis Biosciences Observer Austria
12 Auspherix Observer uk
13 Basilea Observer Switzerland
14 BioFilm Control Observer France
15 Bioversys Observer Switzerland
16 Biovertis Observer Austria
17 Blueberry Therapeutics Observer uk
18 Cantab Anti-infectives Observer uk
19 Deinobiotics Observer France
20 Destiny Pharma, Ltd. Observer uk
21 Discuva Observer uk
22 Eligo Bioscience Observer France
23 Evotec Observer UK/Germany
24 FAB Pharma Observer France
25 Helperby Observer uk
26 IMMT Observer Slovenia
27 Immunsystem AB Observer Sweden
28 Lamellar Biomedical Observer uk
29 Maat Pharma Observer France
30 MGB Biopharma Limited Observer uk
31 Mutabilis Observer France
32 Naicons (New Anti Infectives Consortium) Observer Italy
33 Northern Antibiotics Ltd Observer Finland
34 Nosopharm Observer France
35 Novabiotics Observer uk
36 OLMIX Observer France
37 Pherecydes Observer France
38 Phico Therapeutics Observer uk
39 Polyphor Ltd Observer Switzerland
40 Procarta Biosystem Observer uk
41 Redx Pharma Observer uk
42 Setlance Observer Italy
43 Setubio Observer France
44 Synamp Pharmaceuticals Observer Netherlands
45 TechnoPhage SA Observer Portugal
46 Vibiosphen Observer France
47 Micreos Observer Netherlands
48 Nabriva Therapeutics Observer Austria
49 Centauri Therapeutics Observer uk
50 Neem Biotech Observer uk